You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm has licensed its test to Abbott, BioMérieux, and Quanterix, and it is working with the US Department of Defense as part of a collaborative approach.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Sales of BioFire FilmArray products accounted for more than half of the growth in the quarter.
Drug-breakpoint updates should provide a clearer regulatory path for AST system makers but it's only one step in the fight against antimicrobial resistance, said Romney Humphries of Accelerate Diagnostics.
The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.
Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.
New investor BioMérieux will explore collaborative opportunities using Qvella's sample treatment technology in complementary markets.
Demand for the BioFire FilmArray panels continued to drive sales in the firm's molecular biology business.
The company also said that net income for the first half of 2017 rose 18 percent year over year to €101 million from €85.7 million.
BioMérieux is deploying consultants to advise hospitals about the most optimal testing options and how to implement them.